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1. Introduction 
Bladder cancer represents a significant worldwide health problem with an estimated 386,300 
new cases and 150,200 deaths in 2008 worldwide. The majority of bladder cancer occurs in 
males and there is a 14-fold variation in incidence internationally. The highest incidence 
rates are found in the countries of Europe, North America, and Northern Africa (Jemal et 
al.2011). Smoking and occupational exposures are the major risk factors in Western 
countries, whereas chronic infection with Schistosoma hematobium (SH) in developing 
countries, particularly in Africa and the Middle East, accounts for about 50% of the total 
burden. The majority of bladder cancers associated with schistosomiasis are squamous cell 
carcinoma (Figure 1). 
Although the majority of bladder cancers, present with disease confined to the superficial 
layer of the bladder wall, approximately 20–40% of the patients will present with or 
subsequently develop invasive cancer. Bladder cancer is morphologically heterogeneous; 
more than 90 % of bladder cancer cases are urothelial (UC, transitional cell, TCC) carcinoma, 
whereas primary squamous  cell carcinoma (SCC), adenocarcinoma, small cell carcinoma 
and other rare tumors are less common (Lopez-Beltran and Cheng, 2006). Urothelial cell 
carcinoma can present mixed with other malignant components (figure 2). These mixed 
forms of bladder histologies include squamous differentiation (present in 20 - 60% of 
bladder cancer cases), adenocarcinoma or glandular differentiation (10%), sarcomatoid (7%), 
micropapillary (3.7%) and lymphoepìtelioma-like carcinoma. About 1 in 25 Western men 
and 1 in 80 women will be diagnosed with bladder cancer (BC) sometime in their life. In 
many developing countries, life expectancy is much lower than Westerns, which is one of 
the reasons why overall BC incidence (not age-specific incidence) is lower in these 
developing countries (Albertson and Pinkel, 2003). It is associated with substantial 
morbidity and mortality. History of Tobacco smoking not only increases the incidence of 
BC, but also it can increase the tumor grade, its  size and the number of tumor lesions 
(Muscheck et al, 2000). Chronic schistosomal cystitis was related for a long period to the 
development of BC in areas endemic for schistosomiasis like Egypt. In these areas, risk 
factors are many, including exposure to schistosomiasis, increased smoking rate and 
exposure to carcinogenic chemicals (Kallioniemi et al, 1992). 
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Fig. 1. Squamous cell carcinoma. Groups of malignant squamous cells show central keratin 
nests formation. Aggregates of calcified bilharzias eggs are seen between groups of 
malignant cells. 
Although smoking is still recognized as a major risk factor of cancers including bladder 
cancer, the increasing incidence of bladder cancer, despite the reduction in smoking in the 
United States, suggests that other environmental factors may be playing an increasing role 
in the development of bladder cancer. Unlike the common belief, risk factors such as 
positive family history, parent’s consanguinity, exposure to pesticides and chronic cystitis 
seem to play now more important roles than bilharziasis and smoking in the development 
of this disease in Egypt, yet reports on larger numbers of patients are needed to support this 
conclusion (Zarzour et al, 2008). 
2. Bladder cancer formation 
Urothelial tumor is characterized by its multifocality. There have been two theories 
proposed to explain the frequency of this Urothelial tumor multifocality.  One theory, the 
monoclonal theory, suggests that multiple tumors arise from a single transformed cell that 
proliferates and spreads throughout the urothelium. The second theory, the field-effect 
theory, explains tumor multifocality as a development secondary to the field cancerization 
effect. In the last scenario, carcinogens cause independent transforming genetic alterations at 
different sites in the urothelial lining leading to multiple genetically defective tumors 
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Fig. 2. Invasive urothelial cell carcinoma. Small groups of cells with glandular differentiation 
on the right are seen infiltrating muscle layer (arrow). Bilharzial granulomas are seen on the 
left. 
(Cheng et al, 2010). That may highlight the existence of different histopathologies in the 
same specimen. A recent study suggests that both field cancerization and monoclonal tumor 
spread may coexist in the same patient (Jones et al, 2005). In this study, molecular evidence 
supported an oligoclonal origin for multifocal Urothelial carcinoma. Field cancerization, 
which is an important cause of multicenteric squamous cell carcinoma (SCC) of head and 
neck postulates that multifocal Urothelial carcinoma arises in the same way. The 
independent transformations are a consequence of external cancer-causing influences. 
Premalignant changes, such as dysplasia or carcinoma in situ (CIS) are often found in 
Urothelial mucosa distant from an invasive bladder cancer. Furthermore, various theories 
have been proposed to combine the two mechanisms. Early or preneoplastic lesions may 
arise independently with specific clone and pseudomonoclonality (Hafner et al, 2002). The 
modern carcinogenesis model suggests that malignancy represents clonal expansion of one 
or a few cancer stem cells that proliferate through asymmetric differentiation and can 
diversify into heterogeneous cancer cell lineages. Asymmetric differentiation means that 
following cell division, one daughter cell retains the capacity to divide again and the other 
daughter cell possesses genetic plasticity, allowing phenotypic variation in the offspring. 
When tumors arise from Chromosomal Somatic Changes (CSC) of progenitor cells, a specific 
set of genomics, epigenomic and/ or microenvironment niche alterations is essential for 
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continued clonal expansion. Therefore, each CSC and its pro/zaxgency possess a unique set 
of genetic, epigenetic and phenotypic features. Genetic alterations of stromal somatic cells 
assist CSCs in the niche to promote cancer development and progression (Cheng and  
Zhang, 2008). Since the sixties of the last century, meaningful chromosomal changes were 
subsequently reported in human cancer. With the establishment of different new methods, 
detection of these changes became more apparent and allowed better understanding of the 
process of evolving of different kinds of cancer. Each new method widened the recognition 
of karyotypic changes, increasing the resolution of cytogenetic details until the limit of 
microscopic visualization were almost reached. The evolution of cytogenetics encompasses 
also molecular approaches such as fluorescent in situ hybridization (FISH) and comparative 
genomic hybridization (CGH) whether metaphasic or array. These techniques have revealed 
novel and otherwise cryptic rearrangements, as well as providing chromosomal information 
for cases in which conventional cytogenetic analysis is not possible (Sendberg and Meloni-
Ehrg, 2010). 
A meta-analysis examining urine markers for surveillance showed that Fluorescence In Situ 
Hybridization (FISH) test had a median sensitivity of 79% and median specificity of 70% in 
detecting genetic abnormalities in cells present in urine using FISH (Van Rhijin et al, 2005). 
The main disadvantages of FISH are the lack of standardization of the criterion for a positive 
test, the low sensitivity of detecting low-grade tumors, its expense, and the need for 
specially trained laboratory personnel to perform the test (Degtyar et al, 2004 & Lokeshwar 
et al, 2005). Combined testing with other assays may improve the effectiveness of this 
biomarker. Several markers have shown promise as noninvasive biomarkers of bladder 
cancer, and some may be useful as therapeutic targets. To date, however, none have found a 
strong niche in clinical care because of the lack of evidence demonstrating that outcomes are 
altered on a practical basis. In addition, at this time, none of these markers can supplant 
cystoscopy, and most add little advantage to the combination of cystoscopy and cytology. 
3. Schistosomiasis  
Schistosomiasis  infect 200 million people according to the World Health Organization and 
is endemic in as much as 76 tropical developing countries. S. hematobium (SH) is associated 
with bladder cancer. Schistosomes are dioecious parasitic blood flukes, which have a 
mammalian host and an intermediate invertebrate host: fresh water snails (Kuper et al, 
2000). There are four human schistosomes :S. haematobium, S. mansoni, S. japonicum, S. 
mekonji. The S. haematobium, like other schistosomes  is dioecious and the adult female 
lives in-copulo in the gynecophoral canal of the male; this species of schistosome lives in the 
venules of the human urinary bladder. Eggs laid in the urinary bladder produce irritation 
and eventual fibrosis, contributing to the events that lead to human carcinogenicity (Fried et 
al, 2011). 
All schistosoma infections follow direct contact with fresh water that harbors free-
swimming larval forms of the parasite known as cercariae. Cercariae penetrate the skin. The 
cercariae shed their bifurcated tails, and the resulting schistosomula enter capillaries and 
lymphatic vessels en route to the lungs. After several days, the worms migrate to the portal 
venous system, where they mature and unite. Pairs of worms then migrate to the vesical 
plexus and veins draining the ureters. Egg production commences four to six weeks after 
infection and continues for the life of the worm, usually three to five years. Eggs pass from 
the lumen of blood vessels into adjacent tissues, and many then pass through the bladder 
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mucosa and are shed in the urine. The life cycle is completed when the eggs hatch, releasing 
miracidia that, in turn, infect specific freshwater snails (Bulinus species).After two 
generations - primary and then daughter sporocysts — within the snail, cercariae are 
released (Ross et al, 2002).  
4. Schistosoma-Associated Bladder Cancer (SA-BC) 
Schistosomiasis was first linked to urinary bladder cancer in Egypt in 1911 (Ferguson et al, 
1911). The incidence of urinary bladder cancer in the Middle East and Africa is greater in 
areas with high rather than low SH prevalence; the aforementioned study noted that 60% of 
the Egyptian population was at risk of infection with SH, with rural school children at 
particular risk because of their proximity to contaminated water. The overall prevalence of 
SH infection in Egypt was 37–48% that decreased due to the antibilharzial campaign to 3 % 
(Ministry of Health and Population, 2004). The urinary bladder cancer accounted for about 
31% of the total incidence of cancers in Egypt that subsequently decreased to 12% in recent 
years. However still, it is the most common type of cancer in males and the second most 
prevalent, after breast cancer, in females (Gouda et al, 2007). In Egypt, Iraq, Zambia, 
Zimbabwe, Malawi and Sudan, the incidence of SA-BC peaks at 40–49 years of age; the male 
to female ratio for bladder cancer is 5:1 in endemic and 3:1 in non-endemic areas. This 
relates to the fact that it is agricultural workers, mainly men, who have daily exposure to 
water infected with SH cercariae. (Makhyoun  et al, 1971). Mechanicaly, there are several 
factors that may contribute to the oncological potential of schistosomia infection. 
Schistosoma ova deposited in the bladder provoke an intense inflammatory reaction, 
associated with the production of oxygen-derived free radicals, which may induce genetic 
mutations or promote the production of carcinogenic compounds (such as N-nitrosamines 
and polycyclic aromatic hydrocarbons) (Marletta 1988 & Rosin et al, 1994) ,leading to 
malignant transformation. Shokeir (2004) showed that schistosomiasis is often accompanied 
by chronic bacterial super-infection, which may in itself predispose to squamous cell (SC) 
neoplasia. Bacteria found to accompany schistosomiasis can promote the formation of N-
nitrosation of amines, adding to those from other sources such as the diet. A 54–81% 
incidence of SCC was found in all cases of bladder cancers in endemic areas, opposed to 3–
10% in Western countries. The higher incidence of SCC is probably due to exposure to 
carcinogens such as N-nitroso compounds that are abundantly present in the urine of 
patients with SH (Tricker et al,1989). International Agency for Research on Cancer (IARC) 
found that the intensity of infection was determined by urinary egg counts and confounded 
by smoking, a recognized cause of bladder cancer in non-endemic countries, and the 
combination was strongly considered. Positive association between bladder cancer and SH 
infection was detected, with odd ratios ranging from 2 to 14. The more heavily infected 
individuals were with this schistosome, the more likely they were to develop bladder 
cancer, and at a younger age (IARC, 1994). 
Most of the pathological findings of schistosomiasis are due to an inflammatory and 
immunological response to egg deposition. Granulomatous areas form around the eggs and 
induce an exudative cellular response consisting of lymphocytes, polymorphonuclear 
leukocytes and eosinophil. The early stage of SH infection is characterized by egg deposition 
in the lower ureters and urinary bladder. Resultant perioval granulomas, fibrosis and 
muscular hypertrophy are seen histologically. In the ureter, lesions can cause stenosis, 
leading to hydronephrosis. In the urinary bladder, masses of large granulomatous 
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inflammatory polyps containing eggs are found at the bladder apex, dome, trigone and 
posterior wall. Polyps may ulcerate and slough, producing haematuria. Hyperplasia of the 
urothelium occurred in 38% of the autopsied SH cases as opposed to 21% in non-infected 
cases; also, metaplasia in 31.6% versus 11.5% and dysplasia in 27.2% versus 8.5% cases were 
found. Late-stage infections were characterized by schistosomal bladder ulcers and sandy 
patches, and irregularly thickened or atrophic mucosa in the posterior bladder or trigone 
area. Histologically, fibrosis with some round cell infiltration was seen; old granulomas 
containing calcified or disintegrating eggs were also seen (Smith and Christie, 1986). The 
inflammatory and fibrotic response to egg deposition could lead to calcification of the 
urinary bladder, infection and stone disease and these changes are frequently associated 
with urinary bladder cancer (EL-Bolkainy et al, 1981). These lesions may be at least partially 
responsible to the reported clinical picture of SA-BC. Furthermore, the following sequence 
of events in SH-induced carcinogenesis has been suggested: chronic infection leads to 
schistosoma eggs being trapped in the bladder wall. Proliferation of cells in the bladder 
mucosa results from constant irritation and inflammation. Clones of neoplastic cells develop, 
stimulated by N-nitrosamines and other environmental carcinogens such as cigarette smoke 
and pesticides (Abdel et al, 2000).  The importance of urinary retention, whether from 
fibrosis and obstruction of the urinary bladder neck or from voluntary causes such as pain 
on urination, in prolonging the exposure of the bladder mucosa to various exogenous and 
endogenous carcinogens was documented. Schistosome-induced urinary stasis allows 
increased absorption of carcinogens and therefore plays an integral role in carcinogenesis. 
Recurrent bacterial urinary tract infections are associated with squamous cell carcinoma of 
the urinary bladder, even in the absence of SH infection (Genile et al, 1985). Carcinogenesis 
of SH involving an initiating and promoting effect has been described. First, the damage 
occurs to the DNA template which, unless repaired, leads to irreversible changes in the 
complementary strand of DNA produced during the S-phase of the cell cycle. Somatic 
mutation results when the altered strand is used as a template. The promotion phase 
followed by stimulation of cell proliferation. Different cancer-associated genes, notably 
protoncogenes/oncogenes and tumor suppressor genes, were known to be associated with 
numerous human cancers; recent efforts have been made to study the specific genes 
involved in the induction of SA-BC. Cell exposed to SH cell total antigen (warm exttract) 
was found to divide faster than those not exposed to the parasite and died 
much less. This was probably due to increased level of bcl2, a protein involved in cancer 
apoptosis that may lead to SH carcinogenic ability in bladder urothelium (Botelho et al, 
2009). The urothelium of mice exposed to SH total antigen showed dysplasia, low grade 
intra-urothelial neoplasm, non-invasive malignant flat lesions in 70 % of the tested mice 
after 40 weeks of exposure. Carcinoma of the bladder frequently harbors gene mutations 
that constitutively activate the receptors tyrosine kinase Ras pathway (Wu, 2005). The Ras 
gene product is a monometric membrane-localized G protein of 21 Kd that functions as a 
molecular switch linking receptors and non-receptors tyrosine kinase activation to 
downstream cytoplasmic or nuclear events. Each mammalian cell contains at least three 
distinct Ras proto-oncogenes encoding closely related but distinct protein, Kras, Hras and 
Nras. Activating mutation in these Ras protein, result in constitutive signaling. Thereby 
stimulating cell proliferation and inhibiting apoptosis. Oncogenic mutations in the Ras gene 
are present in approximately 30% of all human cancer (Adjer, 2001). Botelho et al (2010) 
used the dysplastic bladders induced by SH in mice and screened them by sequencing for 
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mutations in Kras codon hotspots gene. They concluded that the parasite abstract has 
carcinogenic ability possibly through oncogenic mutation of Kras gene. 
5. Genetic changes in SA-BC 
Among the most common genetic changes in bladder cancer is the loss of heterozygosity 
(LOH) on chromosomes 9p and 9q, which is found regardless of tumor grade and stage 
(Jacobs et al,2010 & McConkey et al, 2010). A prospective study stated that there was no 
evident line of demarcation between schistosomiasis-associated and non schistosomiasis-
associated bladder cancer in terms of LOH of microsatellite markers on chromosome 9. This 
suggests that data obtained from schistosoma-associated bladder cancer can be extrapolated 
to bladder cancer induced by a schistosomiasis independent mechanism (Abdel Wahab et al, 
2005). DNA microsatellites are highly polymorphic repeats found throughout the genome, 
and microsatellite markers can detect cancer-associated alterations in genetic material, 
including microsatellite instability and LOH (Nielsen et al, 2006). A more recent analytical 
tool that has been developed to detect genomic instability in urinary DNA uses small 
nucleotide polymorphisms (SNPs). SNP chips have a potential advantage over microsatellite 
analysis in that they can screen more than 300 genetic loci at once compared with 13-20 loci, 
which leads to a greater sensitivity of the detection of molecular changes (Hoque et al, 2003). 
6. Cytogenetics for understanding carcinogenesis 
Carcinogenesis is a complex process in which normal cell growth is modified as a result of 
the interaction of multiple factors, including xenobiotics and endogenous constituents. 
Carcinogenic process results from the accumulation of both genetic and epigenetic changes 
that are driven by instability of cellular genome and alterations in inter- or intra-cellular 
communication, which disrupt the cell proliferation regulation process (Loeb and loeb, 
2000). Cytogenetics is concerned with the task of finding recurrent (repeated) or specific 
abnormalities associated with cancer, and continues to provide crucial diagnostic and 
prognostic information. In current practice, cytogenetic data often serve as a guide in other 
studies, ranging from the exploration of cytogenetic findings with various methodologies, 
singly or in combination, including fluorescence in situ hybridization (FISH), polymerase 
chain reaction (PCR), or microarray-based technologies such as comparative genomic 
hybridization (CGH), both metaphasic (mCGH) and array (aCGH), to the use of 
immunohistochemical techniques by the pathologist. Cytogenetic data also provide key 
background information for the recognition and identification of genes (and their networks) 
involved in cancer.  Progress in understanding the cytogenetic and molecular basis of 
neoplastic transformation has strengthened the conception of cancer as a genetic disease. 
Thus, the finding of apparently normal karyotypes in abnormal cells presents an enigma. It 
can be assumed that cryptic genetic changes are involved in such cases. Newer technologies 
highlight the more complicated and perplexing aspects of cancer that have eluded more 
traditional cytogenetic studies. For example, molecular studies have demonstrated fusion 
genes associated with many tumors like prostate and lung cancers that are not discernible 
cytogenetically. These findings raise the strong possibility that more epithelial carcinomas, 
which are usually associated with numerous or complex karyotypic alterations, will be 
shown to have cryptic primary genetic alterations (Sandberg et al,2010) 
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7. Requirements and limitations of cancer cytogenetic studies 
Cytogenetic techniques require the presence of dividing cells (preferably in the metaphase 
stage) for the visualization of chromosomes. Thus, fresh specimens are necessary for 
establishing either short-term or long-term cultures (Sandberg, 1990, Brigge and Sandberg, 
2000, Sandberg and Chen, 2001& Gersen and Keagle, 2005). Nevertheless, useful genetic 
information can be obtained from fixed specimens with appropriate FISH or other molecular 
techniques (Gersen and Keagle, 2005). Cytogenetic changes represent genetic mechanisms 
that are thought to be responsible for the biology of the respective clinical conditions, and 
have become important components of diagnostic and prognostic criteria. There are two 
different classes of genetic alterations associated with cancer: activation of oncogenes and 
inactivation of tumor suppressor genes. Rearrangements are a common source of activating 
mutations. Another scenario is exemplified by chromosome translocations, inversions, or 
insertions that lead to formation of fusion oncogenes. The oncogene fusion mechanism has 
received increased attention, because many of these fusions lead to activation of protein 
tyrosine kinases (PTKs) in various types of cancer. Most of the cytogenetic changes involve 
activation of receptor proteins, especially PTKs. Receptor PTKs are a highly regulated family 
of proteins in normal cells, but may undergo activating mutations or structural alterations to 
become oncoproteins in human malignancies. As already noted, oncogenic activation of 
PTKs can result from genetic lesions such as point mutations, deletions, or overexpression 
by gene amplification. Alternatively, chromosomal rearrangements such as translocations, 
inversions, and insertions that lead to formation of an oncogenic gene fusion can involve 
receptor PTK or other PTK encoding genes as fusion partners. Another type of gene 
rearrangement involves tumor suppressor genes, whose products normally serve as brakes 
on cell growth and runaway cell proliferation. Inactivation of tumor suppressor genes leads 
to uncontrolled cell proliferation and downregulation of apoptosis (programmed cell 
death)(Jones and Baylin, 2002 & Feinberg and Tycko, 2004). The activation of oncogenes 
sometimes results from complex genetic rearrangements. In each of the fusion genes the 
kinase domain of the neural-associated receptor tyrosine kinase gene is fused to an 
activating domain of another gene. The same genes may be altered in a number of different 
tumors, but apparently at varying chronologies in tumor development and associated with 
different genetic changes. In many tumors, a specific translocation may be the only 
alteration present. Many cases, however, display additional structural or numeric 
karyotypic changes that may be responsible for, or at least are associated with, disease 
progression(Sandberg, 1990). The relevance of additional abnormalities is also reflected by 
alterations in the expression of a number of genes apart from those involved in the 
translocations. The exact cause or causes of these additional alterations is unknown, and it 
remains uncertain whether the primary translocation per se is responsible for the basic 
genetic process underlying the tumor genesis. These additional changes usually vary from 
tumor to tumor, even among tumors with the same diagnosis. Tumors with specific 
translocations may exhibit a variety of anomalies, with or without additional chromosome 
changes, at the molecular level. Carcinomas being diagnosed relatively late in their 
development, thus allow for the genesis of chromosomal rearrangements in addition to the 
primary genetic event. Although some of the chromosomal changes have been related to 
prognosis and tumor biology yet, few recurrent or repeated chromosomal anomalies have 
been identified as characterizing these tumors (Teixeira et al, 2006). 
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MicroRNAs (miRNAs) constitute a rapidly developing field of study at many levels. The 
miRNAs are short segments of RNA (~22 bases in length) that affect mRNA functions, most 
often by suppressing translation of the protein product or by promoting degradation of 
them. An important value of miRNAs is that they can be detected and quantified in a 
variety of samples, including plasma and formalin-fixed, paraffin-embedded tissues. This 
makes them a valuable testing tool, particularly in the clinical arena(Wijnhoven et al, 2007, 
Grady and Tewari, 2010 & Ferracin et al, 2010) 
In cancer, the combination of cytogenetic and molecular studies (FISH, SKY, PCR, CGH, and 
related methodologies) can more clearly define pathogenetic pathways and the biologic 
functions of molecular markers than either approach alone. Such a dual approach should 
lead to less empiric and more biologically oriented approaches to tumor classification and, 
ultimately, to more efficient clinical use of biomarkers (Wang,2002 & Balsara et al, 2002). 
Findings based on the combination of cytogenetic and molecular approaches have improved 
the criteria for diagnosis of cancer. The hypothesis that specific clones of spontaneously 
evolving aneuploidies or karyotypes, rather than specific mutations, generate the 
individuality of cancers (Fabarius et al, 2008), may apply to at least some of, if not all, the 
conditions .Cancer development not only depends on genetic alterations but also on 
epigenetic changes (Jones and Baylin, 2007).  These changes modify gene expression through 
DNA methylation, histone modifications, chromatin remodeling, and/or the expression of 
noncoding RNA(Esteller, 2007 & Zaratiegui et al, 2007). 
Epigenetic gene silencing in cancer was thought to be restricted to focal events that silenced 
isolated genes (Smith and Costello, 2006). However, recent findings have indicated that 
epigenetic silencing can extend to a whole chromosomal region and has been reported to 
involve DNA methylation and/or histone modification in various cancers (bladder, breast, 
colorectal, and prostate cancer) (Coolen et al, 2010). 
The development of cancer is often a multistage process where the disruption of specific 
subsets of genes can result in cells expressing a malignant phenotype. However, the series of 
mutations leading to malignancy has only been elucidated for a small number of human 
cancers (e.g., polyposis of the colon, retinoblastoma). There has been no entirely specific 
cytogenetic aberration identified for bladder cancer, but various nonrandom deletions, gains 
of chromosomes, polyploidisation, and formation of isochromosomes have been observed 
(Gibas and Gibas, 1997). 
8. Bladder cancer cytogenetics and epigenetics 
Chromosome 1 has been reported as being the most frequently involved chromosome in 
rearrangements; other chromosomes commonly reported in bladder cancer include 
chromosomes 3,5,7, and 9 (Heim and Mitelman, 1995). Yunis and Soreng (1984) suggested 
that there was a relationship between chromosomal fragile sites and oncogenesis. It is 
believed that fragile sites provide regions of the genome that are more susceptible to 
damage and that this contributes to the carcinogenic process because of subsequent changes 
to gene function or dosage.  Bladder cancer is a very heterogenous disease cytogenetically, 
which suggests that the pathogenesis of the disease may not be consistent for every case. A 
possible scenario of pathogenesis could be the disruption of a nonconsistent set of cell 
regulatory genes compounded with disruption to genes that have a phenotypic effect on the 
bladder. Sustained disruptions to fragile regions as a result of prolonged exposure to 
clastogens in vivo are likely to lead to enduring chromosomal rearrangements and 
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associated gene alterations. The heterogeneity of cytogenetic findings in bladder cancer 
hints that there might be different “fingerprints” or accumulations of genetic changes that 
individually lead to bladder cancer and that fragile sites may be providing a gateway for 
oncogenesis for some cases. Different combinations of these damaged sites could result in 
varying cancer phenotypes, depending upon which particular genes were located at the 
sites susceptible to the mutagens. 
Protoncogenes encode proteins that ultimately enhance cell proliferation. Events that 
convert  protoncogenes to oncogenes can lead to uncontrolled cell proliferation and 
carcinogenesis (Badawi et al, 1995).  The RAS oncogene and its potential association with 
urinary bladder cancer was studied, though still not totally clear. The RAS oncogene 
encodes a 21-kDa protein that affects signal transmission between the nucleus and tyrosine 
kinase receptors. H-RAS activation was estimated in bladder cancer to range between 7% 
and 17%, with its expression being similar with or without concurrent schistosomal 
infection. The TP53 tumor suppressor gene, located on the short arm of chromosome 17, 
encodes a protein that regulates DNA damage repair and controls aspects of the cell cycle 
involving cellular apoptosis and senescence. TP53 mutation results in a reduction of DNA 
damage surveillance leading to instability of the genome and malignant transformation 
(Strohmeyer and Slamon, 1994). The overexpression of the BCL-2 gene in SA-BC patients 
was found to be up-regulated in squamous but not transitional cell cancers of the urinary 
bladder. Therefore, this BCL-2 overexpression is consistent with the predominance of SCC 
in SA-BC. Upregulation  of this gene overrides programmed cell apoptosis increasing the 
risk of genomic instability and may interact with various proto-oncogenes facilitating 
tumorigenesis. Mutations of TP53 were found in 73% of tumors, BCL-2 expression in 32% 
and abnormalities of both TP53 and BCL-2 in 13%. Loss of the normal reciprocal control 
mechanism for apoptosis was suggested in the subset of patients with overexpression of 
both TP53 and BCL-2 (Chaudhary et al, 1997). 
Furthermore, cyclooxygenase-2 is overexpressed in SA-BC. The quantitative relationship 
between cyclooxygenase-2 expression and tumor grade was statistically significant. The 
cyclooxygenase-2 role in the complex multi-stage process of SA-BC carcinogenesis was 
proposed: pro-inflammatory cytokines such as interleukin-1, tumor growth factor-β and 
tumor necrosis factor-alpha, are generated by activated macrophages in the inflammatory 
lesions. These cytokines and growth factors are potent inducers of cyclooxygenase-2 
production. By-products of uncontrolled cyclooxygenase activity together with endogenous 
genotoxins produce oxidative and nitrosative stress creating lipid peroxidation by-products. 
Additional mutations are induced: TP53, H-RAS, deletion of p16 and p15, increased 
epidermal growth factor receptor, c-erb-2 and tumor necrosis factor-alpha. Increased 
prostaglandin production up-regulates cyclooxygenase-2, decreases killer T-cell activity, 
increases BCL-2 and glutathione-S-transferase. These changes increase tumorgenicity by 
decreasing cell apoptosis, creating immunosupression. Prostaglandin products of 
cyclooxygenase-2 cause tumor progression and eventual metastasis by down-regulating 
adhesion molecules, increasing the degradation of extracellular matrix and increasing 
angiogenesis (El-Sheikh et al, 2001). 
9. Natural history of SA-BC 
The association between SA-BC and SH was established through case-controlled studies and 
through the close correlation of the incidence of bladder cancer with the prevalence of SH 
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within different geographic areas. Moreover, the association was based on the frequent 
association of tumors with the presence of parasitic eggs and egg-induced granulomatous 
pathology involving bladder tissues  (Figure 2). Despite that linkage between SH and 
bladder cancer, only limited data are available on cytopathologic findings in SA-BC. The 
cellular mechanisms linking SH infestation with bladder cancer formation are not yet 
defined. In some cases, severe metaplasia in bladder urothelium may represent a 
precancerous transformation, whereas in others it may merely serve as a marker of 
prolonged inflammation, which is associated with high cancer risk (Hodder et al, 2000). 
Keratinizing or adenomatous metaplasia per se has a strong association with cancer 
formation in patients with chronic irritation due to bladder stones, chronic infection, or 
prolonged catheterization. 
SA-BC was defined by characteristic pathology (i.e., squamous carcinoma, transitional cell 
carcinoma, or adenocarcinoma, rather than mainly transitional) and cellular and molecular 
biology that differ from non-Schistosoma-associated bladder cancer (NSA-BC). Few studies 
have analysed the cytogenetic and molecular genetic abnormalities in SA-BC and some 
compared DNA copy number changes in SA-BC and NSA-BC (Kallioniemi et al, 
1992,Tsutumi et al, 1998, Muscheck et al,2000,  Fadl-Elmula et al, 2002 & Albertson and 
Pinkel, 2003). Further future studies are needed to characterize the genetic alterations in 
schistosomal bladder tumors and their role in bladder cancer induction. 
These studies used metaphase CGH to obtain overview of chromosomal alterations in SA-
BC. The value of pooled DNA in aCGH was shown to be advantageous in detecting 
recurrent changes associated with specific histopathologic or clinical features (Kendziorski 
et al, 2005).    Two more recent studies used aCGH, rather than metaphase CGH (Armengol 
et al, 2007 & Vauhkonen et al, 2007). Array CGH provides higher density region-specific 
coverage and direct mapping of aberrations to the genome sequence, as well as higher 
throughput (Albertson and Pinkel, 2003).  This ensures greater accuracy in comparing two 
groups of tumors (e.g., SA-BC and NSA-BC). Muscheck et al. (2000) demonstrated deletion 
similarities in Schistosoma-associated transitional cell carcinoma (SA-TCC) and 
Schistosoma-associated squamous cell carcinoma (SA-SCC), compared to what has been 
previously reported by Kallioniemi et al. (1992) on NSA-TCC and Tsutsumi et al. (1998) on 
NSA-SCC. The previous investigators (Kallioniemi et al,1992,Tsutsumi et al,1998, Muscheck 
et al, 2000, Fadl-Elmula et al, 2002 &  Albertson and Pinkel, 2003) used the technique of CGH 
on individual tumor tissues, not pooled tissues of similar pathologies. Armengol et al. (2007) 
used an excellent technique of combining similar pathological types into pools of tissue 
arising from patients having similar pathological subtypes. These pooled DNAs revealed 
recurrent primary changes covering secondary changes that vary from case to case. The 
pooled specimens of SA-BC tumors showed no schistosomiasis specific changes, compared 
with pools of NSA tumors. The comparison between SA-TCC and NSA-TCC and that 
between SA-SCC and NSA-SCC gave similar results. DNA copy number profiles of urinary 
bladder SA adenocarcinoma revealed similarities to that of SA-TCC and SA-SCC reported 
by Vauhkonen et al. (2007). The results in these two publications showed that the detailed 
analysis of individual genes revealed a set of genes with the same copy number changes in 
all bladder carcinomas, including both SA and NSA tumors. Armengol et al. (2007) 
concluded that there are no major cytogenetic differences among different urinary bladder 
epithelial tumors, regardless of the suspected carcinogen. All the detected imbalances in SA-
BC have been repeatedly reported in NSA-BC that suggested that cytogenetic profiles of 
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chemical- and Schistosoma-induced carcinoma are largely similar in the reports of 
Muscheck et al. (2000) and Fadl-Elmula et al. (2002). Patients having SA-BC usually present 
late with more advanced stage, due to the repeated SH infestations having similar 
symptoms. The decreased intensity of schistosomal infestation in Egypt led to a changing 
pattern of the clinicoepidemiologic features of SA-BC. A decreased SCC/TCC ratio (increase 
in the percentage of TCC and decrease in that of SCC), lowering of the tumor stage and 
increase in the mean age incidence and percentage of pelvic nodal involvement have been 
reported. The reported clinicoepidemiologic differences between SA-BC and SNA-BC are 
now continuously decreasing and the features of SA-BC is slowly approaching that of NSA-
BC as reported by Koraitim et al. (1995) and Zaghloul et al. (2008). These changing features 
were attributed to the decreased intensity of schistosomal infestation in the urinary bladder, 
as a higher degree of schistosomal infestation and egg deposition was found more 
frequently with SCC and a lower with TCC (Zaghloul et al, 2008 & Zaghloul, 2010). 
Furthermore, these changes are repeatedly evident with the predominance of TCC over the 
SCC type, and a decrease of male predominance. If these changes continue with the same 
rate, bladder cancer in Egypt is expected to become identical in features to that of Western 
countries in the near future (Gouda et al, 2007). 
10. Clinical presentation  
Clinical presentations in SA-BC and SNA-BC are similar with few minor differences. 
Hematuria, dysuria and necroturia are the main symptoms in both situations. However, SA-
BC patients usually had experienced these symptoms beforehand as a result of simple 
schistosomal cystitis. This may be the reason of their relatively late presentation. Table (1) 
showed the postcystectomy pathological staging in SA-BC and SNA-BC large studies. The 
early stages (Pa, Pis, P1) were fewer in SA-BC than that in SNA-BC in both the Urothelial 
and non-urothelial pathology. The pelvic nodal involvement was nearly similar in SA-BC 
(range: 16.7% - 25.5%) , Urothelial SNA-BC (range: 16.3% - 45%) and non-urothelial SNA-BC 
(21.8% - 23%). The clincopathologic differences between SA-BC and SNA-BC were 
previously summarized as late presentation, with younger median age and a higher 
percentage of squamous cell carcinoma category (Zaghloul, 1994). 
11. Treatment of non-muscle invasive (superficial) bladder cancer 
Treatment of superficial bladder cancer remains to be transurethral resection and bladder 
biopsy (TURBT) with and without intravesical BCG or chemotherapy instillation. Although 
this treatment type is very popular in Urothelial cancer, it is less popular in non-urothelial 
SNA-BC and SA-BC, probably due to the rarity of the non-invasive stages and the presence 
of many lesions either precancerous or cancerous in the bladder mucosa. 
12. Treatment of muscle-invasive bladder cancer 
Radical cystectomy  
Muscle-invasive bladder cancer is mostly treated with radical cystectomy in many parts of 
the world. Radical cystectomy procedure includes removal of the bladder, seminal vesicles 
and prostate together with perivesical fat and peritoneal coverage, in addition to bilateral 
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Author Number of 
Patients 
PTa,is,1 
% 
PT2 
% 
PT3 
% 
PT4 
% 
Nodal 
involvement 
Pure Urothelial Carcinoma (SNA-BC) 
Bassi  
et al (1999) 
338 32.8 19.8 42.0 19.8 NM 
Stein  
et al, (2001) 
1057 39.9 23.5 23.5 13 23.3 
Cheng  
et al, (2003) 
303 36.1 28.6 25.5 9.9 16.3 
Shariat  
et al, (2006) 
958 22 35 31 12 23 
Urothelial & Non-urothelial (SNA-BC) 
Rogers  
et al, (2006) 
955 21 33 32 14 23 
Lughezzani  
et al, (2010) 
12003 13.4 38.9 28.1 19.6 21.8 
Scosyrev  
et al,(2009) 
1422 14.8 29 29.3 26.8 
Urothelial & Non-urothelial (SA-BC) 
El Said  
et al, (1997) 
420 1 3.8 70.7 24.5 16.7 
Zaghloul, 
(1996) 
357 0 33.3 47.9 18.8 24.4 
El Makresh  
et al,(1998) 
185 7 25 64 7 16 
Zaghloul  
et al, (2006) 
192 3.6 28.1 51.6 16.7 25.5 
Ghoneim  
et, (2008) 
2720 10.5 63.9 16.6 9.0 20.4 
Zaghloul  
et al, (2008) 
5071 1.9 30.1 54.9 13.1 21.9 
Khaled  
et al, (2005) 
180 1.2 5.8 14.1 11.5 16.6 
Ali-El-Dein, 
(2009) 
180 10.0 62.8 25.0 2.2 18.3 
Table 1. Postcystectomy pathological stages and nodal involvement in pure Urothelial and 
mixed Urothelial and non-urothelial schistosoma-non associated and schistosoma associated 
bladder cancer in large series. 
endopelvic lymphadenectomy (with varying level of dissection) in male patients. In females, 
it includes removal of the bladder, its perivesical fat and peritoneal coverage, urethra, uterus, 
ovary and anterior wall of the vagina (anterior pelvic excentration) (Ghoneim et al, 1997 & 
Stein et al, 2001). A review of recent literature of treatment results of different types of 
bladder cancer showed that applying the same treatment yielded nearly the same level of 
results if comparing the same pathological stage (Zaghloul, 2006 & Zaghloul et al, 2006). 
Similar 5-year overall survival rates were found in SA-BC, pure Urothelial and combined 
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Urothelial and non-urothelial SNA-BC types (Table 2). The results were slightly higher in 
Stein et al. (2001) (NSA-BC) and Zaghloul et al.(2006) (SA-BC) as both studies reported 
neoadjuvant or adjuvant radiotherapy and /or chemotherapy as a part of treatment in more 
than one third of their patients. Furthermore, this conclusion applies for comparison of 
disease-free survival, overall survival, or local control rates for radical cystectomy or even in 
adjuvant and neoadjuvant radiotherapy types of treatment for SA-BC and NSA-BC 
(Zaghloul, 2006 & 2010). The treatment end-results of radical cystectomy was not affected by  
 
Author 
Patients # PT1 PT2 PT3 PT4 
Nodal 
involvement 
Pure Urothelial Carcinoma (SNA-BC) 
Cheng  
et al, (2003) 
218 --- 50 28 17 11 
Stein et al, (2001) 1054 74 81/68* 47 44 35 
Medersbacher  
et al, (2003) 
507 76 62 40 49 26 
Takahashi  
et al, (2004) 
466 81 74 47 38 50 
Dhar et al, (2006) 385 --- 63 19 NM 9 
Ho et al, (2009) 148 77 68 65 11 37 
Manoharan  
et al, (2009) 
432 79 60 43 17 22 
Urothelial & Non-urothelial (SNA-BC) 
Nishiyama  
et al, (2004) 
1113 82 84/69* 59 43 35 
Niu et al, (2008) 356 --- 73/44* 22 0 8 
Gupta  
et al, (2008) 
502 90 78 70/58* 46 NM 
Urothelial & Non-urothelial (SA-BC) 
Ghoneim  
et al, (1997) 
1026 73 66 47/31* 19 23 
El Mekresh  
et al, (1985) 
185 83 41 21 
Khaled  
et al, (2005) 
180 55 12 6 
Zaghloul  
et al, (2006) 
192 100 100/47 40 44 31 
Zaghloul  
et al, (2007) 
216 100 51 40 30 31 
Ghoneim  
et al, (2008) 
2720 82 75/53 40 30 27 
*= a/b, NM = not mentioned 
Table 2. The 5-y survival of each pathological stage in Schistosoma-non associated and 
schistosoma associated bladder cancer patients in large radical cystectomy patients. 
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the association with schistosomiasis, nor tumor cell type (Urothelial or non-urothelial) in 
most of the recently published literatures (Ghoneim et al, 1997, Stein et al, 2001, Zaghloul et 
al, 2006) (Table 2). Favorable end-results were reported for patients with pathologically 
organ confined disease. These results were constant for both SA-BC (ranged from 47% to 
83%), and SNA-BC (ranged from 50% to84%). However, the results were significantly worse 
when reporting upon locally advanced tumors (PT3N0M0, PT4aN0M0 or Any N). Again, 
these worse results were experienced by both SA-BC and SNA-BC patients (Ghoneim et al, 
1997 & 2008,Stein et al, 2001,Gschwend et al, 2002, Chang et al, 2003, Medersbacher et al, 
2003, Nishiyama et al, 2004, Takahashi et al, 2004, Rogers et al, 2006 & Lughezzani et al, 
2010). Regardless of the old belief that aberrant differentiation leads to worse results, yet 
many authors reported similar results of these aberrant variants to UC when comparing 
stage to stage. Rogers et al (2006) reported a 5-year progression-free survival rate of 60±2% 
after radical cystectomy for UC and 55±11% for SCC. This difference was statistically 
insignificant. Patients with UC or SCC had statistically significant higher progression-free 
survival rates than non-UC non-SCC patients including those having adenocarcinoma. 
Another study containing considerable number of adenocarcinoma patients was conducted 
using 17 Surveillance, Epidemiology and End Results (SEER) and it showed a difference of 
statistical significance in adenocarcinoma patients who underwent RC at a more advanced 
disease stage than their UC counterparts. Another recent study using a similar SEER 
database demonstrated that SCC was more aggressive than Urothelial cancer after adjusting 
for common prognostic factors, such as stage and grade (Scosyrev et al, 2009). Scosyrev et al 
(2009) concluded that SCC was an independent predictor of mortality among patients with 
stage III and IV disease, and among patients with stage I and II disease who did not 
undergo cystectomy as part of their treatment. Therefore, squamous histology was not 
associated with increased mortality among patients with stage I and II disease when treated 
with cystectomy. Moreover, Ploeg et al (2010) studied all invasive bladder cancer cases 
treated in The Netherlands during a 12 year period of (1995-2006). They concluded that the 
relative survival of muscle-invasive adenocarcinoma patients were equal to that of UC 
patients. For stage II and III disease, adenocarcinoma patients had even better outcome. 
Muscle-invasive SCC patients showed worse survival regardless of stage. In SA-BC, 
Ghoneim et al (2008) demonstrated that SCC (1345 patients) had 10 year overall survival rate 
(OS) of 53.05% (95% CI: 51-57) compared to 48.49% (44-53 for pure UC (705 patients) and 
51.18 % (CI: 45-58) for adenocarcinoma (262 patients). Those patients who had UC with 
squamous or adenomatous metaplasia (286 patients) showed a lower 10-year OS of 42.78% 
(CI: 36-49). The lowest 10-year OS was experienced by those patients who had 
undifferentiated pathology (122 patients) having 10-year OS of 34.23 (CI: 24-45). It is clear 
from this large-number single institution study that the OS of SCC, UC and adenocarcinoma 
were similar and having the same profile. They demonstrated that although the univariate 
analysis was significant (Undifferentiated carcinoma had much lower OS), the multivariate 
analysis proved that tumor cell type is not an independent working factor determining the 
OS. The only significant prognostic factors were stage, grade and pelvic nodal involvement. 
Many authors cautiously concluded that RC treatment end-results were not affected by 
tumor histology or etiology but affected by other prognostic factors like stage, grade, nodal 
involvement, lymphovascular invasion, angiogenesis, P53, P21, Retinoblastoma genes (Rb) 
and other biological factors. These prognostic and predictor factors were shown in many 
SA-BC and SNA-BC studies to have varying weight effect (Ghoneim et al, 2008,Scosyrev et 
al, 2009,Ploeg et al, 2010 & Zaghloul, 2010). 
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13. Preoperative and postoperative radiotherapy 
The rationale of preoperative radiotherapy is to prevent intraoperative seeding of tumor 
cells in the operative field and to sterilize microscopic extensions in the perivesical tissues. 
In the English literature, there are 6 randomized trials addressing the issue of adding 
preoperative radiotherapy to RC. Two of these 6 studies were on SABC (Awwad et al, 1979 
& Ghoneim et al, 1985). Only one (Awwad et al, 1979) showed the benefit of adding 
preoperative radiotherapy. Most of the other 5 studies showed this effect on high stage and 
high grade tumors. On the other hand, there were no differences in statistical values in 
earlier cases. Meta-analysis of these randomized studies showed a corrected odd ratio of 
0.94 (95% CI: 0.57-1.55), indicating no benefit for adding preoperative radiotherapy in BC 
(Huncharek et al,1998). 
Postoperative radiotherapy (PORT) has the advantage of dealing with microscopic cells that 
are easier to sterilize. It allows better identification of the group of patients that may benefit 
from this adjuvant therapy. One large prospective randomized trial proved the benefit of 
PORT in locally advanced SA-BC. The 5-year disease-free survival (DFS) rate was 49 and 44 
% for hyperfractionated (HF) and conventional fractionation (CF) PORT, respectively 
compared with 25% for cystectomy alone patients (Zaghloul et al,1992). This effect was 
constant across all tumor cell type, all muscle-invasive stages and grades in SA-BC. These 
results were replicated in a non-randomized prospective controlled Radiation Therapy 
Oncology Group (RTOG) trial on SNA-BC (Reisinger et al,1992). The results ot the 2 studies 
were nearly identical when compared stage by stage (Zaghloul, 1994). The only difference 
was the high GIT late complication rate reported by Reisinger et al study. They reported 
37% (15 out of 40 patients) developed intestinal obstruction after PORT. Nine out of these 15 
patients required surgery and 3 died. On the contrary, Zaghloul et al (1992) reported 5% and 
18% all grades of late GIT complications for the HF and CF respectively. Only 4% and 5% 
out of the HF and CF group respectively necessitated surgical interference. Similar low 
levels of late GIT complications were experienced by other retrospective studies reported on 
SA-BC and SNA-BC (Cozzarini et al,1999, Zaghloul et al,2002, Zaghloul et al, 2006). 
Abdel Moneim et al (2011) compared, in a prospective randomized trial, preoperative and 
postoperative radiotherapy in SA-BC. They administered the same dose of 50 Gy in 5 weeks 
to both groups. The study reported both similar treatment end-results and late complication 
rates for the two randomized pre- and postoperative groups. 
14. Neoadjuvant and adjuvant chemotherapy 
Neoadjuvant and adjuvant chemotherapy have been utilized in bladder cancer, in an 
attempt to improve the outcome for patients with high risk muscle-invasive disease. At least 
50% of these patients developed distant metastasis after radical cystectomy. Several meta-
analysis of prospective, randomized trials indicated that patients undergoing neoadjuvant 
chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) prior to 
cystectomy have an approximate 5.0 – 6.5 % survival advantage over those who underwent 
surgery alone (Winquist et al, 2004 & Vaughn et al, 2005). However, some investigators still 
argue that this neoadjuvant advantage is small and chemotherapy might be better targeted 
to those at highest risk of relapse after surgery. Furthermore, many elderly patients or who 
have comorbidities will not tolerate MVAC chemotherapy. Therefore, many investigators 
tried adjuvant chemotherapy in a supposed more favorable situation. In reality, adjuvant 
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chemotherapy yielded a modest, statistically significant improvement in survival over 
cystectomy alone (Vale, 2006 & Ruggeri et al, 2006). 
The Egyptian bladder cancer cooperative group compared Neoadjuvant chemotherapy 
using gemcitabine-cisplatin regimen to cystectomy alone in 109 SA-BC patients,  in a 
prospective controlled randomized study. The one-year survival rate was 54% for the 
cystectomy alone patients compared to 69% for the neoadjuvant chemotherapy patients 
(Khaled et al, 2003). 
15. Bladder preservation trimodality treatment 
Since the late 1980s, many centers investigated the bladder preservation strategy as an 
alternative to radical cystectomy. The rationale of this strategy depends on 3 goals: first, 
eradication of the local disease, second, elimination of potential micrometastasis and third, 
maintenance of the best possible quality of life (QoL) through organ preservation (Rodel, 
2004). Several treatment protocols were carried out by different investigators. However, 
they all characterized 3 main and essential procedures with varying timing and varying 
minute details. The first main procedure is maximal TURBT. This is to be followed by 
neoadjuvant chemotherapy or radiochemotherapy (second procedure) and then after 
cystoscopic assessment, followed by either radical radiotherapy or consolidation 
radiochemotherapy for the complete responders (third procedure). There was another 
group treated with radiochemotherapy after TURBT. Cystoscopic assessment will segregate 
the complete responder (CR) for bladder-conserving management and those showing less 
than CR to undergo salvage cystectomy (Zaghloul and Mousa,2010).  The 5-year OS rates 
ranged between 39% and 58% and the 5-year survival with native bladder preservation 
ranged from 36% to 43% (Tester et al, 1993,Kachnic et al, 1997, Shipley et al, 1998, Sauer et al, 
1998  & Arias et al, 2000). Saba et al (2010) reported similar results for UC (SA-BC and SNA-
BC) in Egypt using a trimodality treatment. Complete remission was achieved in 79% of 
cases after initial radiochemotherapy using gemcitabine- cisplatin regimen. The 5-year OS 
rate for patients with initial CR was 68% which is comparable to the results in SNA-BC in 
the western countries treated with trimodality therapy. Moreover, Sabba et al (2010) found 
that the association with schistosomiasis had no significant impact on the results of therapy 
for their patients. 
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